Howard Beall arrived at The University of Montana in July 1997 as an Assistant Professor. He earned a Ph.D. in Medicinal Chemistry at the University of Florida in 1991 under the supervision of Professor Kenneth Sloan. He completed postdoctoral training in biochemical and molecular toxicology under the guidance of Professor David Ross at the University of Colorado Health Sciences Center and served there as an Assistant Research Professor and Assistant Professor before coming to UM. He was promoted to Associate Professor in September 2000.
The goal of this project is to utilize innovative molecular modeling and synthetic approaches to design and produce safe and effective NQO1-directed lavendamycin antitumor agents. A trained medicinal chemist and toxicologist with more than 18 years experience in the field of antitumor quinone drug discovery, Dr. Beall will serve as the PD/PI on this project. He will oversee all aspects of the project from training of the graduate student (Alison Kearns) and undergraduate student (Emily Eickholt) to interpretation of the data and publication of the results. Although his primary scientific role will be to coordinate the pharmacological and toxicological experiments, he also has experience in synthetic and computational chemistry. Dr. Beall will work closely with his collaborators, Dr. Gerdes (computational modeling; Director of the Molecular Computational Core Facility, University of Montana) and Drs. Behforouz and Sammelson (lavendamycin synthetic chemistry; Ball State University), on the design of new compounds and interpretation of data. Another collaborator, Dr. Ross (University of Colorado-Denver), will supervise training for the mouse xenograft studies and will consult on experimental methods. Both Dr. Beall and Ms. Kearns have extensive experience in conducting experiments with mice and are certified by the University of Montana Laboratory Animal Resources facility for handling mice.
Hassani, M., Cai, W., Koelsch, K.H., Holley, D.C., Rose, A.S., Olang, F., Lineswala, J.P., Holloway, W.G., Gerdes, J.M., Behforouz, M. and Beall, H.D. Lavendamycin antitumor agents: structure-based design, synthesis and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies. J. Med. Chem. 51:3104-3115 (2008). PMID: 18457384.
Gajewski, M.P., Beall, H., Schneider, M., Stranahan, S.M., Mosher, M.D., Rider, K.C. and Natale, N.R. Bis-anthracenyl isoxazolyl amides have enhanced anticancer activity. Bioorg. Med. Chem. Lett. 19:4067-4069 (2009). PMCID: PMC2731571.
Cai, W., Hassani, M., Karki, R., Walter, E.D., Koelsch, K.H., Seradj, H., Lineswala, J.P., Mirzaei, H., York, J.S., Olang, F., Sedighi, M., Lucas, J.S., Eads, T.J., Rose, A.S., Charkhzarrin, S., Hermann, N.G., Beall, H.D. and Behforouz, M. Synthesis, metabolism, and in vitro cytotoxicity studies on novel lavendamycin antitumor agents. Bioorg. Med. Chem. 18:1899-1909 (2010); PMID: 20149966.
Mirzaei, Y.R., Weaver, M.J., Steiger, S.A., Kearns, A.K., Gajewski, M.P., Rider, K.C., Beall, H.D. and Natale, N.R. Improved synthesis of 3-aryl isoxazoles containing fused aromatic rings. Tetrahedron 68:10360-10364 (2012); PMID: 23526841.
Newsome, J.J., Hassani, M., Swann, E., Bibby, J.M., Beall, H.D. and Moody, C.J. Benzofuran-, benzothiophene-, indazole- and benzisoxazolequinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1. Bioorg. Med. Chem. 21:2999-3009 (2013); PMID: 23635904.
Keyari, C.M., Kearns, A.K., Duncan, N.S., Eickholt, E.A., Abbott, G., Beall, H.D. and Diaz, P. Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties. J. Med. Chem., 56:3806-3819 (2013); PMID: 23574193.
Duncan, N.S., Beall, H.D., Kearns, A.K., Li, C. and Natale, N.R. Ethyl 3-(9-chloro-10-oxo-9,10-dihydroanthracen-9-yl)-5-methylisoxazole-4-carboxylate. Acta Cryst. E70:o315-o316 (2014); PMID: 24765016.
Yilmaz, A., Mohamed, N., Patterson, K.A., Tang, Y., Shilo, K., Villalona-Calero, M.A., Davis, M.E., Zhou, X.-p., Frankel, W., Otterson, G.A., Beall, H.D. and Zhao, W. Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations. Int. J. Environ. Res. Public Health, in press, (2014).
CEHS © 2015 — All Rights Reserved